RECOMBINANT HUMAN HYALURONIDASE-FACILITATED SUBCUTANEOUS IMMUNOGLOBULIN FOR IDIOPATHIC INFLAMMATORY MYOSITIS: A MULTICENTER OBSERVATIONAL STUDY

被引：0
|
作者：
Palermo, A. [1 ]
Bettiol, A. [1 ]
Urban, M. L. [1 ]
Barilaro, A. [2 ]
Danieli, M. G. [3 ]
Capassoni, M. [4 ]
Guiducci, S. [4 ]
Campochiaro, C. [5 ,6 ]
Dagna, L. [5 ,6 ]
Canti, V. [7 ,8 ]
Rovere-Querini, P. [7 ,8 ]
Cardelli, C. [9 ]
Mosca, M. [9 ]
Emmi, G. [1 ]
机构：
[1] Univ Firenze, Dept Expt & Clin Med, Florence, Italy
[2] Careggi Univ Hosp, Neurol Unit 2, Florence, Italy
[3] Polytech Univ Marche, Dept Clin & Mol Sci, Clin Medica, Torrette Di Ancona, Italy
[4] Univ Firenze, Dept Clin & Expt Med, Rheumatol Unit, Florence, Italy
[5] IRCCS Osped San Raffaele, Milan, Italy
[6] Univ Vita Salute San Raffaele, Immunol Unit Rheumatol Allergy & Rare Dis, Milan, Italy
[7] IRCCS San Raffaele Inst, Milan, Italy
[8] Univ Vita Salute San Raffaele, Div Immunol Transplantat & Infect Dis, Milan, Italy
[9] Univ Pisa, Dept Clin & Expt Med, Rheumatol Unit, Pisa, Italy
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2022年 / 81卷
关键词：
D O I：
10.1136/annrheumdis-2022-eular.4827
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
POS0922
引用
收藏
页码：761 / 761
页数：1
相关论文
共 50 条
  • [41] A Randomized Clinical Trial of Recombinant Human Hyaluronidase-Facilitated Subcutaneous Versus Intravenous Rehydration in Mild to Moderately Dehydrated Children in the Emergency Department
    Spandorfer, Philip R.
    Mace, Sharon E.
    Okada, Pamela J.
    Simon, Harold K.
    Allen, Coburn H.
    Spiro, David M.
    Friend, Keith
    Harb, George
    Lebel, Francois
    CLINICAL THERAPEUTICS, 2012, 34 (11) : 2232 - 2245
  • [42] Long-Term Efficacy, Adverse Events, and Tolerability of Recombinant Human Hyaluronidase-Facilitated Subcutaneous Infusion of Immunoglobulin G in Patients Aged ≥18 Years with Primary Immunodeficiency Diseases
    Wasserman, Richard L.
    Stein, Mark
    Kobrynski, Lisa
    Gupta, Sudhir
    Grant, J. Andrew
    Rubinstein, Arye
    Engl, Werner
    McCoy, Barbara
    Leibl, Heinz
    Yel, Leman
    JOURNAL OF CLINICAL IMMUNOLOGY, 2017, 37 : S53 - S53
  • [43] Four Patients with Refractory Pericarditis Treated with Concurrent Hyaluronidase-facilitated Subcutaneous Immunoglobulin and Anti-interleukin 1 Therapy
    Gans, Melissa D.
    Eisenberg, Rachel
    Rubinstein, Arye
    JOURNAL OF CLINICAL IMMUNOLOGY, 2019, 39 : S38 - S39
  • [44] Interim analysis of a postauthorization safety study on long-term safety of hyaluronidase-facilitated subcutaneous immunoglobulin 10% in primary immunodeficiency disease in Europe
    Ellerbroek, P. M.
    van Paassen, P.
    Hanitsch, L.
    Plebani, A.
    Schmidt, R. E.
    van Hagen, P. M.
    Wang, P.
    Fielhauer, K.
    Leibl, H.
    Yel, L.
    SWISS MEDICAL WEEKLY, 2019, : 17S - 17S
  • [45] Real-World Usage of Hyaluronidase-Facilitated Subcutaneous Immunoglobulin 10% in Patients with Multiple Myeloma Diagnosed with Secondary Immunodeficiency Disease
    Szabo, Agoston Gyula
    Sanchez-Ramon, Silvia
    Siffel, Csaba
    Anderson-Smits, Colin
    Mccoy, Barbara
    Kamieniak, Marta
    BLOOD, 2023, 142
  • [46] Hyaluronidase-Facilitated Subcutaneous Immunoglobulin 10% in Patients With Primary Immunodeficiency Diseases: Interim Analysis of Adverse Events in a Global Post-Authorization Safety Study
    Rubinstein, Arye
    Bridges, Tracy A.
    Wedner, H. James
    McNeil, Donald
    Wasserman, Richard L.
    Tachdjian, Raffi
    Stryk, Steven V.
    Tarpay, Martha M.
    Fielhauer, Katharina
    Leibl, Heinz
    Yel, Leman
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2019, 143 (02) : AB117 - AB117
  • [47] Assessing hyaluronidase-facilitated subcutaneous immunoglobulin 20% (fSCIG 20%) pharmacokinetics, safety and tolerability in primary immunodeficiency diseases: phase 2/3 study design
    LWasserman, Richard
    Leavis, Helen
    Nagy, Andras
    Carrasco, Paz
    Anderson-Smits, Colin
    McCoy, Barbara
    Bauer, Alexander
    Chu, Liang-Hui
    Freedman, Immanuel
    Li, Zhaoyang
    CLINICAL IMMUNOLOGY, 2024, 262
  • [48] TOLERABILITY AND EFFICACY OF FACILITATED-SUBCUTANEOUS INFUSION OF HUMAN IMMUNOGLOBULIN G, 10%, AND RECOMBINANT HUMAN HYALURONIDASE (IGHY): SUBSET OF STUDY PATIENTS WITH PRIMARY IMMUNODEFICIENCIES (PI)
    Wasserman, R. L.
    Melamed, I.
    Stein, M.
    Puck, J.
    Gupta, S.
    Engl, W.
    Leibl, H.
    Gelmont, D.
    Schiff, R. I.
    JOURNAL OF CLINICAL IMMUNOLOGY, 2012, 32 : 155 - 156
  • [49] Long-term efficacy, safety, and tolerability of recombinant human hyaluronidase-facilitated subcutaneous infusion of immunoglobulin (Ig) (fSCIG; HyQvia(®)) in immunodeficiency diseases: real-life data from a monocentric experience
    Francesca Angelotti
    Riccardo Capecchi
    Daiana Giannini
    Ornella Mazzarella
    Valeria Rocchi
    Paola Migliorini
    Clinical and Experimental Medicine, 2020, 20 : 387 - 392
  • [50] TOLERABILITY AND EFFICACY OF FACILITATED-SUBCUTANEOUS INFUSION OF HUMAN IMMUNOGLOBULIN G, 10%, AND RECOMBINANT HUMAN HYALURONIDASE (IGHY) IN PATIENTS WITH PRIMARY IMMUNODEFICIENCY (PI)
    Stein, M.
    Wasserman, R. L.
    Melamed, I.
    Rubinstein, A.
    Puck, J.
    Gupta, S.
    Engl, W.
    Leibl, H.
    McCoy, B.
    Gelmont, D.
    Schiff, R. I.
    JOURNAL OF CLINICAL IMMUNOLOGY, 2012, 32 : 135 - 136
12345